The cation-independent mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF2R or IGF2R) traffics IGF2 and M6P ligands between pre-lysosomal and extra-cellular compartments. Specific IGF2 and M6P high-affinity binding occurs via domain-11 and domains-3-5-9, respectively. Mammalian maternal Igf2r allele expression exceeds the paternal allele due to imprinting (silencing). Igf2r null-allele maternal transmission results in placenta and heart over-growth and perinatal lethality (>90%) due to raised extra-cellular IGF2 secondary to impaired ligand clearance. It remains unknown if the phenotype is due to either ligand alone, or to both ligands. Here, we evaluate Igf2r specific loss-of-function of the domain-11 IGF2 binding site by replacing isoleucine with alanine in the CD loop (exon 34, I1565A), a mutation also detected in cancers. Igf2rI1565A/+p maternal transmission (heterozygote), resulted in placental and embryonic over-growth with reduced neonatal lethality (<60%), and long-term survival. The perinatal mortality (>80%) observed in homozygotes (Igf2rI1565A/I1565A) suggested that wild-type paternal allele expression attenuates the heterozygote phenotype. To evaluate Igf2r tumour suppressor function, we utilised intestinal adenoma models known to be Igf2 dependent. Bi-allelic Igf2r expression suppressed intestinal adenoma (ApcMin). Igf2rI1565A/+p in a conditional model (Lgr5-Cre, Apcloxp/loxp) resulted in worse survival and increased adenoma proliferation. Growth, survival and intestinal adenoma appear dependent on IGF2R-domain-11 IGF2 binding.
The function of the fifteen homologous extra-cellular domains of the cation-independent mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R or IGF2R) include the binding, trafficking and extra-cellular internalisation of ligands, such as Insulin-like growth factor 2 (IGF2), mannose 6-phosphate (M6P) modified lysosomal proteases and plasminogen1. The specific IGF2 and M6P high affinity binding to IGF2R occurs via domain 11, and domains 3, 5 and 9, respectively1. The structural basis of the binding interaction of IGF2 and domain 11 of IGF2R has been determined at atomic resolution, including a mechanism to account for structural co-evolution of IGF2 binding to IGF2R in relation to genomic imprinting2. With respect to the latter, an exon splicing enhancer (ESE) was identified in monotremes based on ESE dependent changes in the amino acid sequence of the hydrophobic CD loop of IGF2R domain 11. This discovery implied that ESE selection lead to acquisition of IGF2 binding to one of its fifteen domains2. Moreover, it also suggested that the evolved and specific IGF2 binding domain of IGF2R was also functionally independent of the other domains of the receptor.
In mammals, Igf2r is also a maternally expressed gene (paternal imprinted or silenced), where allele expression is dependent on the ‘parent of origin’3. The phenotype of the disrupted (null) maternal derived allele (Igf2r-m/+p) in the mouse is associated with over-growth and perinatal lethality, and has been documented by at least three independent groups. The results have all shown placental and embryonic overgrowth by E12.5, a disproportionate overgrowth and tissue specific cardio-pulmonary phenotype and lethality in the early perinatal period, when compared to wild-type littermates4,5,6,7,8,9,10. The cardio-pulmonary phenotype comprises disproportionate cardiac enlargement relative to other body organs, and pulmonary haemorrhage, with associated generalised oedema. This was proposed as the underlying mechanism of lethality, also observed using a conditional Igf2r loxp-null allele10. The phenotype also appears strain dependent, but it remains unclear what the functional mechanisms are with respect to associated strain dependent modifier loci11. Mammalian Igf2r and Igf2 expression are mainly mono-allelic during post-implantation embryonic and placental tissues, except in humans, where both alleles are frequently expressed (loss of imprinting, bi-allelic expression)12. As with the placenta, the embryonic heart is a known site for both Igf2 and Igf2r expression. The implications are that the placenta and heart over-growth are dependent on increased local IGF2 ligand supply. For the heart, the location of Igf2 expression within the epicardium is proposed to regulate cardio-myocyte growth, supporting a trophic-paracrine mechanism of local IGF2 ligand delivery as opposed to an endocrine effect13. The increased Insulin-like growth factor 1 receptor/insulin receptor mediated signaling by increased bioavailable IGF2 arises because of the impaired extra-cellular clearance of IGF2 when IGF2R protein function is disrupted. The increased IGF2 supply following loss of Igf2r is also potentially amplified by the combination with increased M6P-lysosomal proteases, especially if the second M6P receptor, the dimeric cation-dependent MPR, is unable to independently rescue M6P-lysosomal supply. The increase in M6P-lysosomal proteases following loss of function of IGF2R can result in release of both IGF2 and IGF1 bioavailable ligands through cleavage of extra-cellular signalling and matrix proteins, such as IGF binding proteins (IGFBP)14. Genetic rescue of the Igf2r−m/+p growth and lethality phenotype in the mouse, however, occurs when Igf2 is co-disrupted, with mice exhibiting the Igf2 null phenotype of proportionate dwarfism (60% of wild-type), suggesting there is no IGF1 dependent growth rescue8.
The relative and specific titration of IGF2 by high affinity binding of M6P/IGF2R domain 11 represents an important growth regulatory mechanism. This evolved mechanism supports the ‘parental conflict’ theory of genomic imprinting. The parental conflict theory proposes that the nutritional resources transmitted to the growing conceptus result from competition between paternal alleles attempting to extract resources for their offspring from the mother (by increasing IGF2 ligand), and from maternal alleles attempting to conserve such resources (by reducing IGF2 ligand through expression of IGF2R)3,15. Differential allele expression of Igf2r is dependent on methylation of the maternal promoter of an anti-sense long non-coding RNA (lncRNA) termed Airn, located within intron 216. Disruption of either the Airn promoter or deletion/truncation of Airn transcripts in the mouse, results in increased paternal allele Igf2r expression relative to the maternal allele, and so bi-allelic expression9,17,18,19. Bi-allelic expression of Igf2r following deletion of Airn region 2 on the paternal allele, results in a proportional growth reduction in embryos and placenta, again attributed to the sequestration of extra-cellular IGF2 and potentially other ligands9. Moreover, the reduced organ specific growth that occurs following IGF2R transgene over-expression has both IGF2 dependent and independent activity20,21,22. The loss-of-function of Igf2r that results in disproportionate embryonic overgrowth and lethality in the mouse, is also mirrored following mammalian somatic cell cloning in sheep, where epigenetic suppression of Igf2r is thought to contribute to ‘large offspring syndrome’23.
The targeting strategy is important to consider when further investigating the phenotypic consequences of the specific loss of function of IGF2R ligand binding domains in the mouse. We previously attempted to generate an allele based on conditional insertion of human IGF2R exon 3–48 cDNA, that we could then introduce human mutations into a humanised mouse model. When targeted to the intron 2 region of murine Igf2r, this allele resulted in trans-splicing of the knock-in human cDNA with the endogenous maternal mouse Igf2r allele, resulting in a hypomorphic allele that exhibited perinatal lethality and disproportionate placental and embryonic growth phenotypes6. The additional consequence of this type of allele targeting strategy in the mouse, for both the Igf2r and Igf2 loci, may also be associated disruption of co-expressed miRNAs. For both the Igf2 and Igf2r loci, inadvertent targeting of miRNA has frequently been detected. For example, disruption of the Igf2 locus can result in loss and gain of both miR-483, and indirectly miR-675 associated with the H19 non-coding RNA. MiR-675 can negatively regulate IGF1R translation, and so may alter the sensitivity of tissues to IGF2 ligand activation24,25. Moreover, Igf2r 3′ UTR appears to be a specific target for several miRNAs, such as miR-195 and miR-21126,27. Overall, these data suggest more targeted strategies are required in order to directly attribute the entire Igf2r loss-of-function phenotype specifically to IGF2 ligand supply alone.
Following our work on the structural and functional basis of the mechanism of IGF2 binding to domain 11 of IGF2R, we have mapped the essential and specific interacting amino acids within the binding domain loops2. Here, for the first time, we introduce a direct mouse knock-in mutation of one of the IGF2 binding residues in the binding site CD-loop of domain 11, that results in replacement of isoleucine, a hydrophobic amino acid,with alanine (I15721 in human, I1565 in mouse). This mutation has been detected in human liver cancer28, along with other loss-of-function mechanisms such as expansion of a polyG tract in colorectal cancer. It has been proposed that tumour growth promotion might result because of increased local IGF2 supply, as a result of the specific loss of IGF2 binding to IGF2R. The phenotype of this single knock-in allele mutation in the mouse (Igf2rI1565A) resulted in a placental and embryonic over-growth phenotype and partial neonatal lethality, with at least 40% of heterozygous mice surviving into adulthood. As a result of this attenuated phenotype, we were able to further characterise the tumour suppressor function using this novel Igf2rI1565A allele in adult intestinal adenoma models.
Mutation of isoleucine 1565 to alanine results in Igf2r domain 11 specific loss of IGF2 binding
Prior to generating a knock in allele of mouse Igf2r, we first established that the intended mutation results in loss of receptor IGF2 binding. A high degree of evolutionary conservation of IGF2R domain 11 sequence and structure between human and mouse allowed us to map mutations of the human binding site to those of the mouse2. The amino acid residue I1572 (mouse I1565) is a key residue in domain 11 that orientates a conserved CD loop hydrophobic residues with respect to F19 and T16 of IGF2 (Fig. 1a). We introduced the I1572A mutation into human extra-cellular domains (1–15) fused at the C-terminal to rat CD4 (domains 3 + 4), biotin acceptor domain and histidine tag, so that we could purify recombinant mutant protein for affinity studies (Fig. 1b). Following transient co-expression in HEK293T cells with biotin ligase expression vectors, wild-type (WT) and mutated (I1572A), human proteins were purified using affinity to a nickel column, followed by immobilisation on a streptavidin coated BIAcore biosensor chips. Binding kinetics to human IGF2, M6P-beta-glucuronidase and plasminogen were determined using surface plasmon resonance. The I1572A mutation significantly reduced IGF2 binding by 100-fold, yet the 1–15 protein domains bound M6P and plasminogen with similar affinities, indicating that the I1572A mutation was specific for IGF2 binding alone (Fig. 1c,d).
Maternal transmission of the Igf2r I1565A knock-in allele results in lethality
A mouse Igf2r targeting vector with exon 34 mutation I1565A was recombined in C57BL6 ES lines, and transformed under positive (puromycin) and negative selection with ganciclovir (Fig. 2a). Southern blots using 5′ and 3′ probes, confirmed orientation of a single copy insert (Fig. 2b, see Supplementary Figs S1–S3 for full blots). Following PCR verification of correct targeting, two lines were bred with a Cre-deleter strain to remove the puromycin selection cassette, but retaining the flp sites. Two lines achieved germ-line transmission, with line 2 being the basis of subsequent experimental breeding (Fig. 2b,c., see Supplementary Fig. S4 for Igf2r PCR).
Previously reported germ-line Igf2r loss of function alleles identified a placental and embryonic overgrowth phenotype (120–135%) detectable by E12.57,8,29. We first evaluated embryonic growth following timed matings using maternal transmission of the knock-in Igf2r allele (Igf2rI1565A/+p). Maternal transmission of either the heterozygote Igf2rI1565A/+p or homozygote allele (Igf2rI1565A/I1565A), resulted in normal Mendelian segregation in utero based on genotyping of 86 pups (see Supplementary Table 1). Despite litter variation, embryo growth (wet and dry weight) appeared significantly greater in Igf2rI1565A/+p heterozygote (114–122%, p < 0.0001) and Igf2rI1565A/I1565A homozygote (118–135%, p = 0.0001) mice compared to that in wild-type littermates (Fig. 3a). An increase in water content was also observed by E17.5, and remained high in heterozygotes by E18.5 (p = 0.0002, Fig. 3b). For placental growth, there appeared greater heterogeneity between genotypes compared to embryos (Fig. 3c), but with an overall increase in water content observed at E18.5 in heterozygotes (112–118%, p = 0.0061, Fig. 3d). Overall, in comparison of the incremental growth with respect to genotype observed in embryos, placenta growth appeared more variable in respect of significant gain in dry weight and water content (Fig. 3).
Following evaluation of 20 litters and 182 pups at birth (perinatal), maternal transmission of the Igf2rI1565A/+p heterozygote allele resulted in normal Mendelian segregation (Table 1). Following breeding to generate homozygotes, however, perinatal homozygote Igf2rI1565A/I1565A pups were significantly depleted in number (~20% of expected pups, Table 1, p = 0.0006, X2 = 14.97). Subsequent survival of older pups (neonates) revealed significantly decreased survival of heterozygotes Igf2rI1565A/+p (40%) following maternal transmission (log-rank test, p = 0.0043), and significantly worse survival for Igf2rI1565A/I1565A homozygotes (log-rank test, p = 0.003), with all the latter pups failing to reach weaning (Fig. 4a). Subsequently, whole body growth (weight) of the surviving Igf2rI1565A/+p heterozygote pups appeared slightly higher than wild-type littermate controls, with a similar trajectory of growth with time, yet this was not statistically different (p = 0.68, Fig. 4b). We interpret these observations with respect to variability in the over-growth phenotype, with pups with the greater over-growth less likely to survive into adulthood. Overall, neonatal whole body weights were greater in surviving heterozygotes Igf2rI1565A/+p compared to wild-type littermates (p < 0.0001, Fig. 4d).
Maternal transmission of the Igf2r I1565A knock-in allele results in tissue specific growth
Heterozygote Igf2rI1565A/+p exhibited evidence of increased organ growth (Fig. 4). Uteri of surviving female heterozygote adult mice appeared grossly enlarged and fluid filled compared to wild-type littermates, consistent with a degree of vaginal atresia, whereas male genitalia appeared proportionate (Fig. 4c). We did not observe extra post-axial digits or a kink in the tail of heterozygote mice, phenotypes previously associated with null alleles of Igf2r. Neonatal heart weights were also greater in surviving heterozygotes Igf2rI1565A/+p (p = 0.008, Fig. 4e). Even though there was a subjective appearance of being larger, dehydration and cadaver deterioration meant we could not accurately determine whole body weights in non-surviving (heterozygote and homozygote) pups at the time of death. The relative proportion of the heart to body weights were non-significantly different in both surviving heterozygotes (0.79%, p = 0.69) and homozygotes (0.81%, p = 0.62), compared to wild-type controls (0.76%), supporting some degree of proportionality of heart growth (paired t- test of log10-transformed ratios). Histological examination revealed enlarged hearts with expanded trabecular areas, with extensive regions of haemorrhage in the lungs of heterozygotes Igf2rI1565A/+p compared to wild-type controls. Overall, the heart-lung phenotypes we assumed to account for perinatal and neonatal mortality in the larger compared to the smaller pups (Fig. 4f). As the assumption was that the heart growth phenotype was due to increased IGF2 supply, we next considered an approach to reverse the heart phenotype, and potentially survival, by using a conditional Igf2 allele combined with a heart specific Cre knock-in line (Nkx2,5.Cre). By conditional generation of loss of Igf2 expression in the heart, we would expect the lethality of Igf2rI1565A/+p to be rescued. Published data has previously shown that the origin of heart Igf2 expression to be mainly from the epicardium, and that by combining Nkx2,5.Cre and Igf2loxp/loxp, ventricular wall thickness (as a measure of cardiac growth) can be specifically reduced13,30. Following breeding with Igf2rI1565A/+p and generating 4 litters and 33 pups, we failed to identify progeny with combined Igf2rI1565A/+p and Nkx2,5.Cre genotypes (not shown). We attributed this outcome to a low statistical likelihood of allele segregation, as both Nkx2.5 and Igf2r are both co-located on mouse chromosome 17 (Chr17:26838664, Chr17:1268406, respectively).
Brain weight was also proportionately greater (at E18.5) in heterozygotes Igf2rI1565A/+p compared to wild-type controls (p = 0.0079, Fig. 5a). Quantification of phospho-histone H3 (pH3) in ventricular coronal sections revealed significant increased labelling in the sub-ventricular and ventricular zones of the embryonic cerebral cortex, consistent with stimulation of cell proliferation of radial glial stem cells and intermediate progenitors, respectively, in heterozygote Igf2rI1565A/+p (Fig. 5b–d). We examined cortical layering with the layer V/V1 marker, CTip2, and did not observe changes in position or thickness of CTip2+ cells, suggesting that migration was unaltered (Fig. 5e,f).
Maternal transmission of the knock-in allele Igf2rI1565A/+p resulted in a mainly proportionate over-growth phenotype and partial neonatal lethality. Since it was only the IGF2 binding capacity of the IGF2R that was disrupted, these phenotypes can be attributed to increased supply of IGF2 ligand. We next attempted to quantify the total amount of tissue IGF2 using Western blots from tissue extracts (placenta, embryo and heart) using an anti- mouse IGF2 antibody. Following electro-transfer, we noted that the pH of the buffer altered whether the mature (7.5 KDa) isoform of IGF2 was transferred compared to the immature (Big-IGF2) isoforms that were also detectable31. Despite these differences, we could not reliably determine any increase in IGF2 in the Igf2rI1565A/+p tissues compared to littermate wild-type controls (data not shown). As the processing of IGF2 away from the cell signaling receptors at the tissue level (IR and IGF1R) accounts for the function of IGF2/M6P receptor and the mouse phenotypes, the total level of IGF2 in the tissue may not be representative of the metabolism of IGF2 in the extra-cellular space, such as following the sequestration of IGF2 by IGF binding proteins. As our phenotype is more subtle and partially lethal compared to the lethality in the complete Igf2r knock-out mouse, we suspect that we do not have the analytical assays of sufficient sensitivity to identify what maybe a less than two-fold effect on IGF2 levels between genotypes. The Igf2 gene is expressed in utero, and not in adult mice, and this might also account for the growth and prolonged survival of a proportion of heterozygote pups, as the wild-type paternal Igf2r allele may be expressed at lower relative levels but be sufficient for compensation of the loss of function on the maternal allele. The timing of IGF2 bio-availability may therefore complicate the analysis of when to measure IGF2 levels, as our previous evidence suggests the majority of mouse embryonic growth Igf2 dependent effects occur between E9-E10 of mouse gestation32. Timing of measurement is supported by the homozygote Igf2rI1565A/I1565A pups that do not express a wild-type Igf2r paternal allele, but exhibited the more severe late gestation phenotype and early perinatal mortality.
Paradoxical effects of Igf2r allelic dosage in the ApcMin intestinal adenoma model
Mutation and loss of heterozygosity of IGF2R occurs in human cancers, including the mutation I1572A in domain 1128,33,34,35,36. In order to further evaluate the potential tumour suppressor function of Igf2r dependent IGF2 regulation, we utilised Igf2rI1565A/+p in a human early stage cancer mouse model. We first validated an intestinal adenoma model based on ApcMin/+ murine model of Familial Adenomatous Polyposis. The Apc Min point mutation results in strain dependent development of beta-catenin driven multiple intestinal adenoma that can be easily quantified by counting from the proximal, middle and distal small intestine, to caecum and colon, all at post-mortem. When ApcMin/+ was combined with bi-allelic expression (gain-of-function) of either Igf2r (Igf2r+m/R2Δ), due to paternal allele deletion of intron 2 Airn imprinting control region, or bi-allelic expression of Igf2 (H19Δm/+p), due to disruption of CTCF binding region of the maternal allele H19 imprinting control region, or both, significant respective alterations in body weight occurred as expected (Fig. 6a). Compared to wild-type littermates, bi-allelic expression of Igf2 and Igf2r resulted in increased (p = 0.002) and decreased body weight (p = 0.0326), respectively. When H19Δm/+p and Igf2r+m/R2Δ were then combined, body weight normalised and was not significantly different from that of wild-type controls (p = 0.2174, Fig. 6a). The expectation based on our previous work in ApcMin/+, suggested that the number of intestinal adenoma (normalised to growth by using small intestinal surface area) would be similarly altered with the changes in size and body weight20,37. In ApcMin/+, H19Δm/+p, there appeared no significant increase in adenoma number, whereas in ApcMin/+, Igf2r+m/R2Δ there was a significant reduction in the middle part of the small intestine (p = 0.0187), compatible with Igf2r having adenoma suppressor function. Paradoxically, when ApcMin/+, H19Δm/+p, Igf2r+m/R2Δ were then combined, significant adenoma progression was observed, with a marked increase in both adenoma number and variation compared to wild-type littermates especially in the distal small intestine (p = 0.0183, Fig. 6b,c). Potential explanations for these unexpected results may be; segregating modifier loci of the ApcMin/+ adenoma phenotype resulting in variation, despite backcrossing mice to C57Bl6/J >10 generations, and alterations in miRNA that associate with genetic disruption of these loci. In order to circumvent some of these potential confounders, we next combined conditional Apc+/loxp and Igf2rloxp/loxp loss of function alleles with intestinal specific Cre transgenes.
Combinations of Igf2r alleles with conditional Apc loxp supports Igf2r function as a tumour suppressor
Following constitutive expression of villin-Cre, the survival of mice (up to 400 days), and the number and growth of intestinal adenoma were unaltered with respect to either the presence or absence of Igf2rloxp/loxp (see Supplementary Fig. S5a–c). Histological examination of small intestinal adenoma showed no phenotypic differences. A similar result occurred when Igf2rloxp/loxp was combined with homozygote Apcloxp/loxp using tamoxifen inducible Lgr5-Cre (Lgr5CreERT2) (see Supplementary Fig. S5d–f). Here, overall adenoma formation in adult mice was more rapid in onset (survival up to 40 days) because of the homozygous disruption (floxing) of the Apc alleles. Again, histological confirmation with anti-IGF2R antibodies, suggested that there was mosaic loss of Igf2r following conditional disruption in adenoma (see Supplementary Fig. S5g). This result suggests the potential for low floxing efficiency of the Igf2rloxp/loxp alleles in intestinal adenoma, that may have masked our ability to quantify significant phenotypic differences.
We next combined homozygote loss of Apc (Lgr5CreERT2, Apcloxp/lox) on a Igf2rI1565A/+p background, and injected tamoxifen into the surviving adult mice. By making the Igf2r loss of function IGF2 specific and constitutive within all intestinal cells with our new knock-in model, we then observed phenotypic differences that were Igf2rI1565A/+p dependent. Significantly, we observed a decreased survival (log-rank, 0.0468), a shift to more proximal small intestinal adenoma (p = 0.0469) and an increase in distal small intestinal adenoma (p = 0.0149), with increased Ki-67 labelling of small intestinal adenoma (p = 0.0302), when comparing to Lgr5CreERT2, Apcloxp/loxp littermate controls (Fig. 7a-d). The introduction of Igf2rI1565A/+p did not alter the distribution of IGF2R protein within adenoma as expected (Fig. 7e). These data suggest that the constitutively expressed domain 11 specific knock-in mutation Igf2rI1565A/+p, supports the function of Igf2r as a tumour suppressor in the Apc dependent intestinal adenoma conditional model.
Phenotypic models of IGF pathway related genes have tended to exhibit gene dosage effects in keeping with some genes being imprinted, such as Igf2 and Igf2r. In addition, haplo-insufficiency and hypomorphic alleles of the signalling receptor Igf1r have effects in relation to aging38,39,40,41. Aside from allelic dosage, the physiological genetic variants that modify Igf2r function remain poorly understood. Although synonymous and non-synonymous polymorphisms of IGF2R are known in human, there remains some debate as to whether they have direct functional effects on IGF2R42,43,44,45,46,47,48,49. Thus, to date there have been no specific point mutations introduced into the mouse germ-line that result in specific loss of function of Igf2r protein domains.
The loss of function of Igf2r maternal expressed allele in mouse development suggest that both loss of mannose 6-phosphate binding and lysosomal enzyme supply may contribute to the disproportionate growth phenotype, as the mechanism of growth regulation of Igf2 appears proportionate to the mechanisms of cell proliferation and cell death at embryonic day 932. By disrupting splicing regulation of both the targeted allele and the endogenous mouse Igf2r allele, we previously generated a reduction in overall IGF2R protein levels and an associated loss of Igf2r function phenotype6. In this previous model, perinatal lethality was dependent on Igf2, and we showed that we could rescue the phenotype by expression of a wild-type endogenous Igf2r allele. These studies provided the impetus to develop more a targeted and specific consequence of a knock-in alanine mutation in a key single residue that disrupts the CD loop binding to IGF2 within the domain 11 IGF2-binding site of IGF2R in the mouse. As we have shown, this mutation results in loss of IGF2 binding capacity by at least 100-fold, and to IGF2 alone. The inheritance of the loss of function allele in the mouse only results in a phenotype when transmitted through the maternal germ-line, indicating the allele did not alter imprinting control. Moreover, the phenotype we describe also differs significantly from that of the previously reported with complete loss-of-function Igf2r alleles, as a significant proportion of neonates survived into adulthood with milder growth phenotypes. These data suggest that the contribution of other IGF2 independent functions of Igf2r contributed to the more severe phenotype associated with complete Igf2r allele disruption previously reported4,5,6,7,8,9,10. The additional functions of IGF2R implicated in the latter models may include the disruption of lysosomal protease clearance and trafficking, potential modification of TGFβ signalling and cleavage of IGFBPs by enzymes such as the PAPP-A protease, resulting in further bioavailable IGF2 that could also promote growth14. We have summarised the growth outcomes of our knock-in Igf2rI1565A/+p allele in relation to the previous literature concerning genetic manipulation of Igf2 and Igf2r on embryonic and placental growth phenotype in the mouse50 (Supplementary Fig. S6).
The assumption is that the increased autocrine, paracrine and endocrine supply of IGF2 contribute to the phenotype observed. In terms of actual quantification of free IGF2 within mouse embryonic tissue, our experience reflects the similar limited data reported in previous publications, that are often complicated by acid-athanol extraction methods that aim to remove IGFBPs prior to ELISA, RIA or Western blots. For example, previous IGF2 quantification of IGF2 are selectively presented in either Western blots51, display limited sample numbers without presenting variation in raw data5,8, or only detected differences at selected embryonic time points (e.g. E12.5), with circulating IGF2 determined by radio-immunoassay7. The use of immuno-histochemistry to detect IGF2 within cells may be informative, but when the underlying mechanism is through extra-cellular ligand bio-availability, quantification of the soluble pool of IGF2 would be problematic using this method in washed tissue sections. These reports highlight the lack of sensitive analytical methods (such as in situ pulse chase methodology) to quantify the real time metabolism of IGF2 intra- and extra-cellularly, both in terms of its expression and delivery, but also its signaling receptor kinetics and receptor-ligand internalisation.
Our phenotypic data confirm that Igf2r domain 11 has an essential developmental role in IGF2 regulation, and that a single point mutation in a wild-type allele of Igf2r renders the protein unable to sequester IGF2, leading to over-growth of the embryo, placenta and heart, and subsequent early lethality. As a result, it is likely that hypomorphic Igf2r alleles with specific disruption of IGF2 binding function would not be expected to be evolutionary selected if they result in reduced viability of the offspring. It is tempting to speculate that one explanation for the subsequent loss of imprinting of IGF2R in human may reflect less selective evolutionary pressure to maintain mono-allelic expression, as the high IGF2 affinity achieved would indicate limited additional benefit of affinity enhancing mutations2.
Circumstantial data from sequencing human cancers and genetic modification of cell lines, have implicated IGF2R as a tumour suppressor gene52,53,54,55,56,57,58,59,60,61,62,63,64,65. Functionally defining the tumour suppressor function of IGF2R in mouse models in vivo has been dependent on the nature of the Igf2r gain and loss of function alleles, and the types of models used. For example, a constitutive YAC transgenic Igf2r gain of function model was shown to rescue Thp (Igf2r loss of function), and also mammary tumour progression in an Igf2 induced mammary tumour model65. This outcome mirrored that of over-expression of a soluble M6P/IGF2R transgene in the regression of intestinal adenoma in the ApcMin model20. For loss of function, however, only a conditional disruption of Igf2r loxp alleles in the liver using an albumin-Cre has been reported, but failed to result in a (pre-) malignant phenotype10. These data also suggest that Igf2r, as with Igf2, regulates a second tumour signal in co-operation with a tumour initiating mutation66. Here we now show, using a Wnt pathway driven model, that existing models of Igf2r imprinting control disruption and the efficiency of conditional Igf2r allele floxing, limited our ability to generate informative loss and gain of-function models. By exploiting the partial survival of maternal allele transmission of Igf2I1565A/+p, we now show in a conditional early intestinal adenoma model (Lgr5-Cre, Apcloxp), that early adenoma growth can be modified by the IGF2 dependent function of Igf2r. These data suggest for the first time that early adenoma growth may be modified by the IGF2 dependent function of Igf2r, extending the potential that selection for IGF2 supply may be a functional driver in the development of colorectal cancer. Cancer genome (CGA) data confirms this hypothesis, with at least 20% of all colorectal cancers having associated increased IGF2 expression67. Whilst these data support the constitutive tumour suppressor function of Igf2r, it remains unknown what the specific cell type(s) are that express Igf2r in order to regulate tumour suppressor activity.
Materials and Methods
Mammalian protein expression and western blotting
Human Embryonic Kidney 293 (HEK293T) cells were grown in Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich St Louis, MO, USA) supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich St Louis, MO, USA) and 1% of penicillin & streptomycin (P&S; Life Technologies Ltd, Paisley, UK) at 37 °C in 5% CO2 incubator. Cells were passaged at 80–100% confluency using Gibco® TrypLE™ Express (Life Technologies Ltd, Paisley, UK).
The 1–15 extracellular domains of human IGF2R were expressed in HEK293T cells as CD4 (domains 3 and 4) fusion protein cloned in the pHLsecAvitag with a 6His and BirA acceptor tags, as previously described68. A synthetic gene was created with the sequence altered to generate the I1572A mutant for human IGF2R (equivalent to mouse I565A), and cloned into the same expression vector following type IIS restriction enzyme digestion. HEK293T cells were also co-transfected with a plasmid for biotin ligase BirA expression and the medium was supplemented with 2 mM biotin. For transfection, DMEM medium (1.6 ml) was mixed with 36 µg of co-transfection expression vector mixture (34 µg of receptor expressing vector, 2 µg of biotin ligase expressing vector) followed by the addition of 144 μl of polyethylenimine (PEI) (1 mg/ml) followed by vortexing, incubation and addition to culture cells.
Biotinylated protein in the supernatant was purified using a PrepEase His-tagged protein purification kit (USB Affimetrix, UK). Proteins that were separated by PAGE were transferred to polyvinylidene fluoride (PVDF) membrane by wet transfer using MiniProtean 3 system, either at 100 V, at room temperature for an hour or at 30 V at 4 °C overnight, in transfer buffer composed of 14.4 g/L glycine, 3.02 g/L Tris and 10% methanol in double distilled water. The PVDF membranes were blocked and probed at room temperature for one hour or at 4 °C overnight. The membranes were washed with Tris-buffered saline with Tween 20 three times (TBS-T was 8.006 g/L NaCl, 2.423 g/L Tris base, 1% Tween20, pH 7.6). Blots were developed using ECL Plus Western Blotting detection system and Amersham Hyperfilm ECL (24 × 30 cm) from GE Healthcare Life Sciences (Little Chalfont, UK). Blocking solutions for PVDF membranes were prepared by dissolving either 3% bovine serum albumin (BSA Sigma-Aldrich St Louis, MO, USA) or 5% skimmed milk in Tris-Buffered saline with Tween 20 (TBS-T). Mouse Anti-His6 peroxidase conjugated monoclonal antibody from Roche (West Sussex, UK) was diluted 1 in 10000 in the blocking reagent to probe poly-histidine tag. To detect biotinylation, high sensitivity streptavidin HRP Conjugate from Pierce (Rockford, Il, USA) was diluted 1 in 20000 in the blocking reagent. Antibodies used included anti-IGF2R (R&D systems, AF2447).
Surface plasmon resonance
Surface plasmon resonance was performed on a BIAcore® T200 for human IGF2 binding to human CD4 domains 3 and 4-IGF2R fusion proteins. For human IGF2 (7.4 KD) and IGF1 (7.7 KD) binding, approximately 1800 response units of biotinylated CD4-IGF2R fusion protein were immobilized on a CM5 chip previously loaded with Streptavidin by amine coupling. Approximately, 200 RU of the receptor was immobilised for higher molecular weight analytes such as bovine β-glucuronidase (290 KD) and human glu-plasminogen (88 KD). In presence of acetate ions, plasminogen exists in an open conformation, and so binding was performed in 150 mM sodium acetate. Kinetic binding experiments were carried out at 25 °C at a 40 μl/min flow rate in HBS-EP binding buffer by injecting solutions of IGF2 from both species ranging from 256 to 0.125 nM for 200 seconds. In order to avoid mass transport effects, dissociation constants (KD) were also confirmed at a range of flow rates (5, 10, 20, 40 and 80 µl/min), and indicated low KD values at flow rates below 40 μl/min. Analyte solutions were then replaced by HBS-EP buffer for 1 hr and followed by a 60 μl injection of 2 M MgCl2 for regeneration of the sensor chip surface. A buffer control and a reference flow cell were included. Data were analysed using the BIAcore T200 Evaluation software version 1.0 and both by fitting the kinetic data to 1:1 binding model and by steady state analysis at equilibrium.
Generation of the Igf2rI1565A allele
All animal work was approved by University of Oxford animal ethics committee, and was performed under a UK Home Office Project Licence (ABH). All regulated procedures were performed according to guidelines, by trained staff. All severity levels and outcomes were monitored throughout, including humane endpoints for breeding and intestinal tumour monitoring. Genetic targeting of Igf2r to insert a point mutation (C57Bl/6NTac-Igf2rtm2760(I1565A)Arte) was generated in collaboration with Artemis-Taconic (Cologne, Germany, Fig. 2). Viable mice were generated bearing the knock-in allele on the paternal allele Igf2r+m/I1565A. Briefly, the pIgf2r-targeting vector was constructed using a PCR based cloning strategy using BAC clones from the C57BL/6J RPCI-731 BAC library (Fig. 2a). The flanking short arm (6.3Kb) contained exons 28–31, followed by a positive PuroR (Puromycin resistance) selection marker flanked by Frt sites into intron 31, the mutation in exon 34 (ATC to GCC to generate I1565A) and the long arm (10.3 Kb) that contained exons 35–42 followed by the thymidine kinase (Tk) negative selection marker. Artemis Taconic C57Bl/6N Tac ES cell lines were transfected and selected homologous recombination clones micro-injected into BALB/c blastocysts (Fig. 2b). The C57BL/6N Tac ES cell line growth and transfection were as described previously6. The final constitutive expressing allele was generated following breeding with Flp deleter mice (Igf2r+m/I1565A), to remove the PuroR, but retaining a single Frt site, used then for genotyping using flanking PCR primers to generate a larger product (302 bp) compared to the wild-type allele (227 bp) (Fig. 2c). Primers used were O3: GGTGCAGGTGTTATGACTGG and O4:AGTACATCAGCCTGTATCCTGG flanking the Frt site. Derived lines were bred against C57Bl/6 N.
Two female and two male Igf2r+m/I1565A mice from lines (A-G02, B-D03) were paired with C57BL/6J wild-type mice and the resulting offspring genotyped. Igf2r+m/I1565A transmitted through the maternal germ-line resulted in identical frequency of neonatal lethality in resulting offspring (see also Results). Males from Igf2r+m/I1565A A-G02 were paired with wild-type C57BL/6J female mice for all subsequent breeding. All other lines were obtained with permission and were backcrossed >10 generations onto C57BL/6J9,69. These lines were: Igf2rR2Δm/+p line, bi-allelic expression of Igf2r resulting from disruption of intron 2 imprinting control region, the H19Δ13kb/+p line resulting in bi-allelic Igf2 expression following disruption of the CTCF boundary, the ApcMin ‘line1’ spontaneous adenoma model70, Igf2lox/loxp (Igf2tmConstancia), Apcloxp/loxp (Apctm1Tno) conditional loxp intestinal adenoma model71, Vil-CreERT2 (Tg(Vil-cre/ERT2)23Syr)72 and Lgr5tm1(cre/ERT2)Cle (129P2/OlaHsd)73 tamoxifen inducible intestinal Cre lines and the cardiac Nkx2.5Cre (C57BL/6J) line. Embryos were staged by taking mid-day on the day of seminal plug detection as embryonic day 0.5 (E0.5). Weighed embryos were fixed in 4% neutral buffered formalin.
Genotyping was performed by PCR using ear clips and standard conditions, as above and previously described37.
Intestinal adenoma phenotype
Induction of Cre with tamoxifen and phenotyping of intestinal adenoma followed post-mortem dissection were performed as previously described37.
IGF2 western blot quantification
In order to quantify levels of bio-available IGF2 in conceptus tissues exhibiting overgrowth phenotype, we dissected placental and embryos from litters collected at E16.5. Placenta, hearts and embryos were dissected apart in ice-cold PBS (4 °C), before weighing, freezing and storage at −80 °C. Whole embryos, hearts and placenta were subject to homogenisation as described6. Following SDS-PAGE without prior acid-ethanol extraction, the proteins and recombinant mouse and human IGF2 positive controls (Gropep) were then electro-transferred overnight at 4 °C to a PVDF membrane in a variety of buffers of different pH and 10–15% methanol, and the blots incubated with Ponceau S to verify equal protein loading. For detection, anti-IGF2 (R&D systems, AF792) at 0.4 µg ml−1 was used as the primary antiobody with an HRP-conjugated secondary antibody (Dako, 1:2000).
Tissue samples were fixed in 4% (v/v) neutral buffered formalin at RT for 24 hr, before dehydration and paraffin embedding. Sections (5 µm) were processed by standard techniques. Briefly, slides were de-waxed in xylene, rehydrated followed by antigen de-masking in sodium citrate buffer (10 mM, pH6.0) in a pressure cooker for 2 min at 125 °C and 10 min at 85 °C. Washed tissue sections (Tris-buffered saline, TBS, pH7.4) were blocked in 10% goat serum/Tween 20© 0.5% (v/v) for 1 hr at RT followed by incubation with primary antibodies; anti-E-cadherin (mouse, 1:200, BD610182, BD laboratories, UK); anti-Ki-67 (rabbit, 1:300, RM9106, Thermo Scientific, USA), Anti-phospho histone H3 (pH3, mouse, 1:1000, Abcam), anti-CTip2 (rat, 1:400, Abcam,), anti-IGF2R (goat, 1:200, AF2447, R&D Systems) and anti-LAMP1 (rat, 1:100, sc19992, Santa Cruz) at 4 °C overnight. After 3 washes in TBS tissue sections were incubated with secondary fluorescent-conjugated antibodies (goat anti-mouse or goat anti-rabbit, Alexa-488, -555, -594, or -647, 1:300, Invitrogen, USA, or goat anti-chicken dylight-550, Abcam, UK) for 2 hr at RT or biotinylated antibodies as per manufacturer’s instructions (Vectastain elite avidin-biotin complex kit, Vector Laboratories). After washing, fluorescent-labelled tissue sections were counterstained with DAPI (1:5000, D9663, Invitrogen, USA) and mounted with Prolong gold anti-fade reagent (P36930, Invitrogen, USA). Fluorescent images were acquired using a confocal microscope Olympus Fluoview FV1000. Sections labelled using a biotinylated secondary antibody were counterstained with haematoxylin, dehydrated through an alcohol series and mounted with Depex mounting medium (Electron Microscopy Sciences, USA).
All statistical analysis utilised Prism Version 8 software. For comparison of conceptus and organ growth by genotype, a one-way ANOVA with pairwise comparisons with wild-type controls were performed where stated with either Bonferroni multiple comparisons test for adjusted p-values, or where stated, with Fishers LSD. For Kaplan-Meier survival analysis, the log-rank test (Mantel-Cox), and for non-parametric comparison, the Mann-Whitney test, were applied, respectively.
All primary data reported in this manuscript is accessible by contacting the corresponding author.
Ghosh, P., Dahms, N. M. & Kornfeld, S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4, 202–212 (2003).
Williams, C. et al. An exon splice enhancer primes IGF2:IGF2R binding site structure and function evolution. Science 338, 1209–1213 (2012).
Haig, D. & Graham, C. Genomic imprinting and the strange case of the insulin-like growth factor II receptor. Cell 64, 1045–1046 (1991).
Barlow, D. P., Stoger, R., Herrmann, B. G., Saito, K. & Schweifer, N. The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. Nature 349, 84–87 (1991).
Eggenschwiler, J. et al. Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. Genes Dev 11, 3128–3142 (1997).
Hughes, J., Frago, S., Buhnemann, C., Carter, E. J. & Hassan, A. B. Maternal transmission of a humanised Igf2r allele results in an Igf2 dependent hypomorphic and non-viable growth phenotype. PLoS One 8, e57270 (2013).
Lau, M. M. et al. Loss of the imprinted IGF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev 8, 2953–2963 (1994).
Ludwig, T. et al. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev-Biol 177, 517–535 issn: 0012-1606, (1996).
Wutz, A. et al. Non-imprinted Igf2r expression decreases growth and rescues the Tme mutation in mice. Development 128, 1881–1887 (2001).
Wylie, A. A. et al. Tissue-specific inactivation of murine M6P/IGF2R. Am J Pathol 162, 321–328 (2003).
Hagan, J. P., Kozlov, S. V., Chiang, Y., Sewell, L. & Stewart, C. L. Intraspecific mating with CzechII/Ei mice rescue lethality associated with loss of function mutations of the imprinted genes, Igf2r and Cdkn1c. Genomics 84, 836–843 (2004).
Lee, J. E., Pintar, J. & Efstratiadis, A. Pattern of the insulin-like growth factor II gene expression during early mouse embryogenesis. Development 110, 151–159 (1990).
Li, P. et al. IGF signaling directs ventricular cardiomyocyte proliferation during embryonic heart development. Development 138, 1795–1805 (2011).
Conover, C. A. et al. Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development. Development 131, 1187–1194 (2004).
Wilkins, J. F. & Haig, D. What good is genomic imprinting: the function of parent-specific gene expression. Nat Rev Genet 4, 359–368 (2003).
Latos, P. A. et al. An in vitro ES cell imprinting model shows that imprinted expression of the Igf2r gene arises from an allele-specific expression bias. Development 136, 437–448 (2009).
Sleutels, F., Zwart, R. & Barlow, D. P. The non-coding Air RNA is required for silencing autosomal imprinted genes. Nature 415, 810–813 (2002).
Stricker, S. H. et al. Silencing and transcriptional properties of the imprinted Airn ncRNA are independent of the endogenous promoter. EMBO J 27, 3116–3128 (2008).
Wutz, A. et al. Imprinted expression of the Igf2r gene depends on an intronic CpG island. Nature 389, 745–749 (1997).
Harper, J. et al. Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res 66, 1940–1948 (2006).
Pravtcheva, D. D. & Wise, T. L. Igf2r improves the survival and transmission ratio of Igf2 transgenic mice. Mol Reprod Dev 75, 1678–1687 (2008).
Zaina, S. & Squire, S. The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms. J Biol Chem 273, 28610–28616 (1998).
Young, L. E. et al. Epigenetic change in IGF2R is associated with fetal overgrowth after sheep embryo culture. Nat Genet 27, 153–154 (2001).
Smits, G. et al. Conservation of the H19 noncoding RNA and H19-IGF2 imprinting mechanism in therians. Nat Genet 40, 971–976 (2008).
Venkatraman, A. et al. Maternal imprinting at the H19-Igf2 locus maintains adult haematopoietic stem cell quiescence. Nature 500, 345–349 (2013).
Dror, S. et al. Melanoma miRNA trafficking controls tumour primary niche formation. Nat Cell Biol 18, 1006–1017 (2016).
Zhang, Y. et al. Cooperative repression of IGF2R translation by miR-195 and RNA-binding protein CUGBP1. Mol Cell Biol (2017).
Byrd, J. C., Devi, G. R., de Souza, A. T., Jirtle, R. L. & MacDonald, R. G. Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations. J Biol Chem 274, 24408–24416 (1999).
Wang, Z. Q., Fung, M. R., Barlow, D. P. & Wagner, E. F. Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/Mpr gene. Nature 372, 464–467 (1994).
Shen, H. et al. Extracardiac control of embryonic cardiomyocyte proliferation and ventricular wall expansion. Cardiovasc Res 105, 271–278 (2015).
Frago, S. et al. Directed evolution of selected IGF2R domain 11 loop residues generates an IGF2 super-antagonist. in submission (2013).
Burns, J. L. & Hassan, A. B. Cell survival and proliferation are modified by insulin-like growth factor 2 between days 9 and 10 of mouse gestation. Development 128, 3819–3830 (2001).
De Souza, A. T., Hankins, G. R., Washington, M. K., Orton, T. C. & Jirtle, R. L. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 11, 447–449 (1995).
Devi, G. R., De Souza, A. T., Byrd, J. C., Jirtle, R. L. & MacDonald, R. G. Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers. Cancer Res 59, 4314–4319 (1999).
Hankins, G. R. et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 12, 2003–2009 (1996).
Kong, F. M., Anscher, M. S., Washington, M. K., Killian, J. K. & Jirtle, R. L. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 19, 1572–1578 (2000).
Matheson, J. et al. Epithelial-mesenchymal transition and nuclear beta-catenin induced by conditional intestinal disruption of Cdh1 with Apc is E-cadherin EC1 domain dependent. Oncotarget 7, 69883–69902 (2016).
Bokov, A. F. et al. Does reduced IGF-1R signaling in Igf1r+/1 mice alter aging? PLoS One 6, e26891 (2011).
Holzenberger, M. et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421, 182–187 (2003).
Jin, C. et al. Histone demethylase UTX-1 regulates C. elegans life span by targeting the insulin/IGF-1 signaling pathway. Cell Metab 14, 161–172 (2011).
Pehar, M. et al. Altered longevity-assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death. Aging Cell 9, 174–190 (2010).
Adkins, R. M. et al. Association of birth weight with polymorphisms in the IGF2, H19, and IGF2R genes. Pediatr Res 68, 429–434 (2010).
Biong, M. et al. Genotypes and haplotypes in the insulin-like growth factors, their receptors and binding proteins in relation to plasma metabolic levels and mammographic density. BMC Med Genomics 3, 9 (2010).
Cheng, I. et al. IGF2R missense single-nucleotide polymorphisms and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 18, 1922–1924 (2009).
Dong, X. et al. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol 36, 206–211 (2012).
Killian, J. K. et al. Mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) variants in American and Japanese populations. Hum Mutat 18, 25–31 (2001).
Petry, C. J. et al. Genetic variation in the type 2 insulin-like growth factor receptor gene and disparity in childhood height. Growth Horm IGF Res 15, 363–368 (2005).
Rezgui, D. et al. Structure and function of the human Gly1619Arg polymorphism of M6P/IGF2R domain 11 implicated in IGF2 dependent growth. J Mol Endocrinol 42, 341–356 (2009).
Savage, S. A. et al. Analysis of genes critical for growth regulation identifies Insulin-like Growth Factor 2 Receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev 16, 1667–1674 (2007).
Sferruzzi-Perri, A. N., Sandovici, I., Constancia, M. & Fowden, A. L. Placental phenotype and the insulin-like growth factors: resource allocation to fetal growth. J Physiol 595, 5057–5093 (2017).
Grandjean, V., Smith, J., Schofield, P. N. & Ferguson-Smith, A. C. Increased IGF-II protein affects p57kip2 expression in vivo and in vitro: implications for Beckwith-Wiedemann syndrome. Proc Natl Acad Sci USA 97, 5279–5284 (2000).
Berthe, M. L. et al. Mannose-6-phosphate/insulin-like growth factor-II receptor expression levels during the progression from normal human mammary tissue to invasive breast carcinomas. Eur J Cancer 39, 635–642 (2003).
Caixeiro, N. J., Martin, J. L. & Scott, C. D. Silencing the mannose 6-phosphate/IGF-II receptor differentially affects tumorigenic properties of normal breast epithelial cells. Int J Cancer 133, 2542–2550 (2013).
Chen, Z., Ge, Y., Landman, N. & Kang, J. X. Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells. BMC Cancer 2, 18 (2002).
Hebert, E. Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep 26, 7–17 (2006).
Iwamoto, K. S., Yano, S., Barber, C. L., MacPhee, D. G. & Tokuoka, S. A dose-dependent decrease in the fraction of cases harboring M6P/IGF2R mutations in hepatocellular carcinomas from the atomic bomb survivors. Radiat Res 166, 870–876 (2006).
Kreiling, J. L. et al. Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer. FEBS J 279, 2695–2713 (2012).
Kuismanen, S. A. et al. Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol 160, 1953–1958 (2002).
Lemamy, G. J., Sahla, M. E., Berthe, M. L. & Roger, P. Is the mannose-6-phosphate/insulin-like growth factor 2 receptor coded by a breast cancer suppressor gene? Adv Exp Med Biol 617, 305–310 (2008).
Li, J. & Sahagian, G. G. Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor. Oncogene 23, 9359–9368 (2004).
Martin-Kleiner, I. & Gall Troselj, K. Mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) in carcinogenesis. Cancer Lett 289, 11–22 (2010).
O’Gorman, D. B., Weiss, J., Hettiaratchi, A., Firth, S. M. & Scott, C. D. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 143, 4287–4294 (2002).
Probst, O. C. et al. The mannose 6-phosphate/insulin-like growth factor II receptor restricts the tumourigenicity and invasiveness of squamous cell carcinoma cells. Int J Cancer 124, 2559–2567 (2009).
Puxbaum, V. et al. M6P/IGF2R modulates the invasiveness of liver cells via its capacity to bind mannose 6-phosphate residues. J Hepatol 57, 337–343 (2012).
Wise, T. L. & Pravtcheva, D. D. Delayed onset of Igf2-induced mammary tumors in Igf2r transgenic mice. Cancer Res 66, 1327–1336 (2006).
Christofori, G., Naik, P. & Hanahan, D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369, 414–418 (1994).
Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
Aricescu, A. R., Lu, W. & Jones, E. Y. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr 62, 1243–1250 (2006).
DeChiara, T. M., Efstratiadis, A. & Robertson, E. J. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345, 78–80 (1990).
Haines, J. et al. Genetic basis of variation in adenoma multiplicity in ApcMin/+ Mom1S mice. Proc Natl Acad Sci USA 102, 2868–2873 (2005).
Shibata, H. et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278, 120–123 (1997).
el Marjou, F. et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186–193 (2004).
Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003–1007 (2007).
We thank Anton Wutz, Randy Jirtle, Shirley Tilghman, Andrew Silver, Robert Schwartz and Alan Clarke (deceased) for mouse lines. Ralph Gareus at Taconic Artemis for genetic manipulation, Richard Stillion for tissue sections, and Hans Hoppe, Andrew Ward and Chris Graham for discussion. We acknowledge Cancer Research UK (ABH and MC, C429), Clarendon-Arab Bank scholarship programme (MS), Doctoral Training Centre (MD) and EPA research Trust (SC, SF, RT) for support.
The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hughes, J., Surakhy, M., Can, S. et al. Maternal transmission of an Igf2r domain 11: IGF2 binding mutant allele (Igf2rI1565A) results in partial lethality, overgrowth and intestinal adenoma progression. Sci Rep 9, 11388 (2019) doi:10.1038/s41598-019-47827-9
Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer—from Basic Research to Potential Clinical Applications
International Journal of Molecular Sciences (2019)
Biology Direct (2019)